<table>
<thead>
<tr>
<th>Title</th>
<th>Category/Subcategory(ies)</th>
<th>Author</th>
<th>Disclosures</th>
<th>Abstract Text</th>
<th>Question</th>
</tr>
</thead>
</table>

ID: 20032

Abstract Submission

Your abstract submission has been received

Print this page

You have submitted the following abstract to the ASRM 2023 Scientific Congress & Expo. Receipt of this notice does not guarantee that your submission was complete or free of errors.

RELATIVE RISK OF CLINICAL PREGNANCY LOSS BY AGE IN UNTESTED VS PRE-IMPLANTATION GENETIC TESTED (PGT-A) EMBRYOS

Keri Bergin, B.S., M.D.1, Isabelle Kate Levin, BA2, Morgan Baird, MPH3, Joseph Lee, BA3, Teresa Cacchione, MS, CGC3, Jenna Friedenthal, M.D.3, Taraneh Gharib Nazem, B.A., M.D.3 and Alan B Copperman, M.D.4, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, NY, (3)Reproductive Medicine Associates of New York, New York, NY, (4)Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York, New York, NY

Title:
RELATIVE RISK OF CLINICAL PREGNANCY LOSS BY AGE IN UNTESTED VS PRE-IMPLANTATION GENETIC TESTED (PGT-A) EMBRYOS

Submitter's E-mail Address:
bergin.keri@gmail.com

Preferred Presentation Type:
Oral or Poster

Study Type:
Retrospective Cohort Study (includes comparator groups)

Category - Subcategory(ies):
Genetics: PGT

* Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.

* I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.

Permissions - Prior Publication or Presentation
This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

ACCME Disclosure
Nothing to disclose. No off-label or otherwise non-approved product use.

Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?
This abstract has been approved by a local Institutional Review Board (IRB) or equivalent.

This data will be submitted for separate scientific abstract and video presentations. The two presentations are NOT identical.

Agree

Applying for an award

Trainee: Yes

Abstract Category:
All Other Categories

Applied for the In-Training Award for Research


2/7
Abstract Text:

OBJECTIVE: PGT-A allows for selection of embryos with the highest reproductive potential. PGT-A can improve pregnancy outcomes per embryo transfer cycle compared to untested embryos, particularly with advancing age. This study attempted to quantify the benefit of PGT-A on reducing clinical pregnancy loss rates (CPLR) by comparing CPLR in untested vs tested embryo transfers and providing the relative risk of CPL with advancing age.

MATERIALS AND METHODS: The study included single frozen embryo transfers (FET) from January 2016 - December 2022. Cycles were divided: Group 1: FET with a single, untested embryo; Group 2: FET with a single, euploid embryo tested with Next Generation Sequencing. Comparative statistics on oocyte age, BMI, anti-mullerian hormone, antral follicle count, endometrial thickness, number of prior transfers, and embryo quality were performed using Mann-Whitney U and chi-square analysis. Relative risks (RR) of CPL between groups were calculated for each age: < 30, 30-34, 35-36, 37-38, 39-40, 41-42, and >42 years. Multivariate logistic regression fitted with generalized estimating equation was performed to compare the odds of CPL between untested and tested FETs. Secondary outcomes included chemical pregnancy, implantation, biochemical pregnancy, and live birth rate.

RESULTS: A total of 11,912 cycles met inclusion criteria: 1397 in Group 1 and 10,515 in Group 2. RR of CPL with untested embryos compared to tested embryos increased with increasing age. At 37-38 years, the rate of CPL became significantly higher in untested vs tested embryos (18.0% vs 8.6% \(X^2(1, N = 1033) = 5.2, p = .002\)) with RR of 2.1. In all ages, there was a statistically significant difference in CPLR between untested and PGT-A cycles (11.6% vs 8.5%, \(p=0.008\)). A multivariate logistic regression adjusted for all variables, including age, showed significantly higher odds of CPL in patients who underwent untested FETs (OR 1.81, CI 1.2-2.7, \(p = .02\)). Secondary outcomes below.

CONCLUSIONS: There is a lower rate of CPL in FETs with a euploid embryo compared to FET with an untested embryo. The relative risk of CPL was 1.3 times higher in untested embryos vs PGT-A tested embryos in patients < 30 years old. This increased to 2.1 times higher risk at 37-38 years, and 8.3 times higher risk at > 42 years with untested embryos. Clinicians should appreciate the significance of increased CPLR with untested embryos in patients of all age groups, as its repercussions can be both physical and emotionally taxing to the patient.

IMPACT STATEMENT: The use of PGT-A is associated with lower odds of clinical pregnancy loss.

<table>
<thead>
<tr>
<th>Rate (%)</th>
<th>Group 1: Untested (n = 1397)</th>
<th>Group 2: PGT-A Tested (n = 10,515)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy Rate</td>
<td>65.71</td>
<td>74.9</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Biochemical Loss Rate</td>
<td>16.78</td>
<td>16.04</td>
<td>0.5641</td>
</tr>
<tr>
<td>Implantation Rate</td>
<td>54.69</td>
<td>62.89</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Clinical Pregnancy Loss Rate</td>
<td>11.57</td>
<td>8.52</td>
<td>0.008</td>
</tr>
<tr>
<td>Live Birth Rate</td>
<td>37.94</td>
<td>46.71</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

First Presenting Author

Presenting Author

Keri Bergin, B.S., M.D.  
**Email:** bergin.keri@gmail.com -- Will not be published

Icahn School of Medicine at Mount Sinai  
Obstetrics, Gynecology, and Reproductive Science  
1176 Fifth Ave, Klingenstein Pavilion  /New York NY 10029  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?  
No - disclosing all COI  
Signature: Keri A. Bergin  
- 2022-02-15 19:09:44

---

**CV Upload:**

[PDF](Keri Bergin CV2023.pdf)

---

**Second Author**

Isabelle Kate Levin, BA  
**Email:** ikl003@jefferson.edu -- Will not be published

Sidney Kimmel Medical College at Thomas Jefferson University  
1025 Walnut St #100  /Philadelphia NY 19107  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?  
No - disclosing all COI  
Signature: Isabelle Levin  
- 2022-02-15 19:09:44

---

**Third Author**

Morgan Baird, MPH  
**Email:** mbaird@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York  
635 Madison Ave 10th Fl  /New York NY 10022-1009  
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?  
No - disclosing all COI  
Signature: Morgan Baird  
- 2022-02-15 19:09:44
Fourth Author

Joseph Lee, BA
Email: jlee@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Joseph Adam Lee
- 2022-02-15 19:09:44

CV Upload:
Joseph Lee CV.doc

Fifth Author

Teresa Cacchione, MS, CGC
Email: tcacchione@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
Reproductive endocrinology and Infertility
635 Madison ave.
Floor 10
New York NY 10022
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Sixth Author

Jenna Friedenthal, M.D.
Email: jfriedenthal@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Jenna B Friedenthal
- 2022-02-15 19:09:44

CV Upload:

Jenna Brooke Friedenthal CV 4.20.21.pdf

Seventh Author

Taraneh Gharib Nazem, B.A., M.D.
Email: tnazem@rmaofny.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Taraneh Gharib Nazem
- 2022-02-15 19:09:44

Eighth Author

Alan B Copperman, M.D.
Email: acopperman@rmany.com -- Will not be published
Icahn School of Medicine at Mount Sinai/Reproductive Medicine Associates of New York
Department of Obstetrics, Gynecology, and Reproductive Science
New York NY
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No - disclosing all COI
Signature: Alan B Copperman
- 2022-02-15 19:09:44

If necessary, you can make changes to your abstract submission until Wednesday, April 26, 2023 at 5:00 pm (EDT).
To access your submission in the future, use the link to your user portal from one of the automatic confirmation emails that were sent to you during the submission.
Or point your browser to https://asrm.confex.com/asrm/2023/gateway.cgi
You will be prompted to login with your ASRM account prior to accessing the user portal. If you do not yet have an ASRM account, the screen will redirect you to the site where you can register for a new account.
When registering for a new ASRM account:

- Please use the email address that is associated with the submission and your first and last name as they appear on the submission when creating this account.